Celltrion has unveiled plans to build its third plant and a global biotechnology research center in Songdo, Incheon, during the Korea Bio-industry forum this week. The company will build a 60,000-liter biopharmaceutical plant to build a multi-type production and supply system and a one-stop research center for complex R&D, process development, and clinical practice. This proposed factory will install a total of eight 7,500-liter bioreactors, as the company is set to respond flexibly to the production of its biopharmaceuticals as its portfolio widens. Timing for the project has the research center being completed in July 2022 and the third plant in May 2023. The third plant will start operation from June 2024.